Achieving Unique Synergies In Antibody Expression

By Rachel Kravitz, Wendy Vredenburgh, Victoria Chrostowski and Greg Bleck

Shortening timelines to generate more productive, stable and high expressing cell lines is the goal of any cell line development program. View the technical poster to learn how combining Catalent’s GPEx^® cell line development technology with Berkeley Lights, Inc.’s Beacon^® platform for clonal cell line selection resulted in stable, higher-expressing clones in a shortened time frame.

CHO pooled cell lines producing two different antibodies were developed using GPEx^® technology. Antibody 1 was identified as easier to express and Antibody 2 was more difficult to express. Clonal cell lines were isolated from both pools using two different methodologies. The first method consisted of two consecutive cycles of cloning using the ClonePix^TM system. The second method consisted of one cycle, using the Beacon^® system. Beacon^® system top clones on average were 1.5-fold higher for Antibody 1 and 3-fold higher for Antibody 2. Unoptimized clonal titers ranged up to 6.8 g/L for Antibody 1 and 2.8 g/L for Antibody 2. Detailed methodologies and clonal variation will be highlighted.